These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2873331)

  • 41. [Oral lisuride in Parkinson's disease].
    Obeso JA; Luquin MR; Martínez Lage JM
    Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
    [No Abstract]   [Full Text] [Related]  

  • 42. Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa.
    Lieberman A; Goldstein M; Neophytides A; Kupersmith M; Leibowitz M; Zasorin N; Walker R; Kleinberg D
    Neurology; 1981 Aug; 31(8):961-5. PubMed ID: 7022259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apomorphine and lisuride infusion. A comparative chronic study.
    Stocchi F; Bramante L; Monge A; Viselli F; Baronti F; Stefano E; Ruggieri S
    Adv Neurol; 1993; 60():653-5. PubMed ID: 8420205
    [No Abstract]   [Full Text] [Related]  

  • 44. The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's disease.
    Rabey JM; Streifler M; Treves T; Korczyn AD
    Adv Neurol; 1990; 53():451-5. PubMed ID: 2122652
    [No Abstract]   [Full Text] [Related]  

  • 45. Pergolide and lisuride in advanced Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
    Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Goodgold A; Pact V; Walker R
    N Y State J Med; 1981 Nov; 81(12):1751-5. PubMed ID: 6949052
    [No Abstract]   [Full Text] [Related]  

  • 47. Comparison of efficacy of lisuride hydrogen maleate with increased doses of levodopa in parkinsonian patients.
    Rabey JM; Treves T; Streifler M; Korczyn AD
    Adv Neurol; 1987; 45():569-72. PubMed ID: 3825734
    [No Abstract]   [Full Text] [Related]  

  • 48. Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study.
    LeWitt PA; Gopinathan G; Ward CD; Sanes JN; Dambrosia JM; Durso R; Calne DB
    Neurology; 1982 Jan; 32(1):69-72. PubMed ID: 7033825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continuous subcutaneous lisuride infusion in OPCA.
    Heinz A; Wöhrle J; Schöls L; Klotz P; Kuhn W; Przuntek H
    J Neural Transm Gen Sect; 1992; 90(2):145-50. PubMed ID: 1463593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.
    Obeso JA; Luquin MR; Martínez Lage JM
    Ann Neurol; 1986 Jan; 19(1):31-5. PubMed ID: 3947037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Vacca L; Olanow CW
    Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A study on the effect and tolerance of lisuride on Parkinson's disease.
    Bayülkem K; Erişir K; Tuncel A; Bayülkem B
    Adv Neurol; 1996; 69():519-30. PubMed ID: 8615174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic effect of lisuride in advanced Parkinson's disease.
    Meneghetti G; Bracco F; Giometto B; Ferla S; Schergna E
    Eur Neurol; 1986; 25(1):74-80. PubMed ID: 3510126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 55. Continuous dopaminergic stimulation in the management of complicated Parkinson's disease.
    Agnoli A; Stocchi F; Carta A; Antonini A; Bragoni M; Ruggieri SA
    Mt Sinai J Med; 1988 Jan; 55(1):62-6. PubMed ID: 3258057
    [No Abstract]   [Full Text] [Related]  

  • 56. Lisuride in extrapyramidal disorders: a possible mechanism of action.
    Bosio A; Bassi S; Govoni S; Spano PF; Trabucchi M; Covelli V; Frattola L
    Adv Neurol; 1984; 40():523-6. PubMed ID: 6695630
    [No Abstract]   [Full Text] [Related]  

  • 57. [Is dopaminergic therapy immunologically rejuvinating? Increased interferon-gamma production with the dopaminergic agent lisuride].
    Poehlau D; Baier JE; Kovacs S; Gallati H; Suchy I; Will C; Schmutz T; Neumann HA; Przuntek H
    Fortschr Med; 1994 Apr; 112(12):174-6. PubMed ID: 8200605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of terguride in patients with Parkinson's disease.
    Suchy I; Rinne UK; Wachtel H
    Adv Neurol; 1987; 45():577-81. PubMed ID: 3548267
    [No Abstract]   [Full Text] [Related]  

  • 60. Efficacy of a low-dose subcutaneous lisuride infusion in Parkinson's disease.
    Hayashi R; Tako K; Makishita H; Koyama J; Yanagisawa N
    Intern Med; 1998 May; 37(5):444-8. PubMed ID: 9652898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.